Satellos Bioscience Inc. is seeing a drop in its stock price, raising concerns about its market performance.
Today, Satellos Bioscience Inc. (MSCL.TO) is facing a tough day, with its stock down 2.51% to close at CA$13.60. This decline comes despite some recent positive news about its clinical programs and FDA designations.
Investor takeaway: Investors should be cautious, as the stock's decline might reflect broader market sentiments or specific concerns among shareholders.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$290.60M
52W high
$18.98
52W low
$6.36
1W change
+13.51%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 26.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+26.6% Upside
Current Price
C$13.95
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
89.4%
Annualized
90-Day Vol
86.8%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$16.68
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$14.81 | C$10.88 – C$20.15 |
| 60 trading days | C$15.71 | C$10.16 – C$24.30 |
| 90 trading days | C$16.68 | C$9.78 – C$28.45 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Satellos Bioscience Inc. Market Cap: CA$290.6 Million
The company’s market cap is relatively modest, indicating investor caution amid ongoing developmental challenges.
Bull case
The recent FDA Fast Track Designation for SAT-3247 could speed up the drug's development timeline, which might lead to significant gains in the future.
Bear case
The current slide in stock price may show investor skepticism about the company's ability to meet expectations, especially given its lack of profit margins and ongoing development risks.
Market Reaction and Performance
Today, Satellos Bioscience Inc. is experiencing a decline in its stock price, down 2.51%. This drop could be influenced by broader market conditions or specific investor concerns. Even with the recent FDA Fast Track Designation for SAT-3247, aimed at expediting development for Duchenne Muscular Dystrophy, the market is reacting negatively.
Future Prospects and Challenges
While the Fast Track Designation could be a catalyst for future growth, Satellos faces significant challenges. The company has yet to report any profit margins, and investor confidence may be wavering as they await tangible results from its clinical programs. Potential investors should weigh the risks carefully before making decisions. For more details on their recent developments, check out the updates on their clinical programs and financial results.
Advertisement
Wealth Awesome Newsroom
The Wealth Awesome Newsroom delivers timely Canadian market updates, earnings, dividends, and stock movers for DIY investors. Coverage is reviewed against public filings and market data feeds.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
